Safeguarding Cell Therapies with High Precision Vector Copy Number (VCN) Profiling

Bulk qPCR and ddPCR report average vector copy numbers (VCN) across cell therapy manufacturing, but population averages conceal critical cellular heterogeneity. Two cell therapy batches can share the exact same bulk average VCN while carrying vastly different single-cell distributions, hiding rare cells with high integration loads that pose insertional mutagenesis risks. Furthermore, pairing bulk ddPCR with flow cytometry relies on separate assays across different cells, forcing cell therapy developers to infer relationships between phenotype and integration. In this application note, learn how the Mission Bio Tapestri® Platform measures vector copy number per cell, transduction status, and surface proteins for functional readout simultaneously in individual cells to improve VCN safety profiling of cell therapy products.

What you will learn

• Per-cell VCN distribution. Two control mixtures with near-identical average VCN (1.92 vs 1.89) carried clearly different single-cell copy number distributions, a separation a ddPCR average cannot make.
• Analyze transduction and VCN together. Reading vector amplicons per cell returned 99.2% to 99.9% sensitivity and 98.8% to 99.6% specificity across two vector systems, with transduction linearity on the CAR vector at R² 0.998 and replicate coefficient of variation of 0.4% to 1.3%.
• Differences in cell lineage integration. Running a surface protein panel alongside the single-cell DNA readout, vector copy number and transduction status are mapped directly to specific cell types. This exposes a lineage-specific integration skew that bulk averages completely hide, including an approximately threefold difference in average VCN between CD4+ (~1.06) and CD8+ (~0.34) T-cell subsets in this study.
• Implications for in vivo cell therapies. By mapping vector copy number and surface protein markers simultaneously in individual cells, this single-cell multiomic readout allows developers to determine precisely which cell types take up vector in vivo and at what copy number providing the lineage-resolved resolution essential for evaluating off-target transduction and insertional safety risks.

What you get with your download

Download the application note to see how Mission Bio Assay Services support cell therapy safety assessment, product characterization, and cell therapy research.

FAQ

What does a single-cell VCN assay measure that ddPCR does not?

It counts vector copy number in each cell rather than an average across pooled input, so it resolves the per-cell copy number distribution and links copy number to a cell’s lineage and phenotype in the same measurement.

How accurate is single-cell VCN compared with ddPCR?

Across defined controls from the National Institute of Standards and Technology (NIST), single-cell VCN profiling matched ddPCR with a regression slope of 0.93 (95% confidence interval of 0.87 to 0.99) and R² 0.98 over copy number 0 to 4, and matched two assays on actual CAR vector at R² 0.99.

Can vector copy number be linked to cell lineage in the same cell?

Yes. By running a surface protein panel simultaneously with the DNA readout on the Tapestri® single-cell multiomics platform, you can measure each cell’s immunophenotype, transduction status, and copy number within the exact same assay. Conventional workflows require separate samples for flow cytometry and ddPCR or qPCR, forcing developers to infer relationships across disconnected datasets.

Why does vector copy number distribution matter for CAR T safety?

With bulk methods like ddPCR or qPCR, two products with identical average vector copy numbers (VCN) can mask completely different underlying copy distributions. Undetected, cells with high copy number elevate the risk of insertional mutagenesis and uncontrolled clonal expansion. By revealing the true per-cell distribution and flagging high copy numbers, single-cell VCN profiling provides the precise cellular resolution needed for robust safety assessments for cell therapies.